Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stiripentol plus carbamazepine in drug-resistant focal epilepsy
2022-001005-43Phase 4Completed
- Sponsor
- Biocodex
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of stiripentol and carbamazepine in Focal Onset Epilepsy, sponsored by Biocodex. Primary endpoint: Description of carbamazepine and stiripentol treatment at each follow-up visit. Started Mar 2022; status: completed.
02
Drugs
stiripentolcarbamazepine
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on 2022-001005-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001005-43.